Financial Results, New Appointments, and Stock Price Movements - Research Report on Salix Pharmaceuticals, Cigna, St. Jude Medical, Zimmer, and CareFusion Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 13, 2013 NEW YORK, November 13, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Cigna Corporation (NYSE: CI), St. Jude Medical, Inc. (NYSE: STJ), Zimmer Holdings, Inc. (NYSE: ZMH), and CareFusion Corporation (NYSE: CFN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Salix Pharmaceuticals, Ltd. Research Report On November 7, 2013, Salix Pharmaceuticals, Ltd. (Salix Pharmaceuticals) announced its Q3 2013 financial results. The Company's net product revenues increased 28.7% YoY to $238.2 million during the quarter. Net income was $47.3 million or $0.71 per diluted share in Q3 2013, compared to net income of $16.5 million or $0.26 per diluted share in Q3 2012. Commenting on the results, Carolyn Logan, President and CEO of Salix Pharmaceuticals, said, "XIFAXAN 550 for the treatment of hepatic encephalopathy continues to demonstrate sustained growth and market penetration. During 10 weeks of the past 12 weeks XIFAXAN 550 achieved a record-high level of total prescriptions." Logan added, "Salix continues to succeed in our mission of being the leading specialty pharmaceutical company licensing, developing and marketing innovative products to healthcare professionals to prevent or treat gastrointestinal disorders. We believe our acquisition of Santarus and the combined assets of our two companies should create a larger, even stronger Salix that will be better positioned to provide solutions for gastrointestinal disorders to patients and healthcare providers." The Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/04fa_SLXP] -- Cigna Corporation Research Report On November 7, 2013, Cigna Corporation (Cigna) announced that the Company named Edward Kim as President and General Manager for the Company's Arizona health plans, along with his current role as President of Cigna Medical Group. According to Cigna, Kim's additional responsibilities include enhancing customer satisfaction through personalized service and helping to improve quality of care by working in collaboration with area health care professionals. Cigna added that his new responsibilities also include ensuring that the Company's product and network offerings meet the evolving needs of the marketplace, assisting employer clients to improve the health and productivity of their workforces, and leading its efforts to serve the community. The Full Research Report on Cigna Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7307_CI] -- St. Jude Medical, Inc. Research Report On November 8, 2013, St. Jude Medical, Inc.'s (St. Jude Medical) stock rose 1.37%, ending the day at $56.99. Over the previous three trading sessions, shares of St. Jude Medical declined 0.94% compared to the S&P 500 which gained 0.43% during the same period. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ] -- Zimmer Holdings, Inc. Research Report On November 8, 2013, Zimmer Holdings, Inc.'s (Zimmer) stock rose 0.26%, ending the day at $88.59. Over the previous three trading sessions, shares of Zimmer declined 0.39% compared to the S&P 500 which gained 0.43% during the same period. The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9db9_ZMH] -- CareFusion Corporation Research Report On November 7, 2013, CareFusion Corporation (CareFusion) reported its Q1 FY 2014 financial results (period ended September 30, 2013). The Company's revenue declined 0.8% YoY to $830 million during the quarter. Net income was $78 million or $0.36 per diluted share in Q1 FY 2014, compared to net income of $84 or $0.37 per diluted share in Q1 FY 2013. Commenting on the results, Kieran T. Gallahue, Chairman and CEO of CareFusion, said, "Our team executed well and delivered solid first quarter results, putting us on the right track for the full fiscal year. I'm pleased with the way our Procedural Solutions team continues to perform across the board, and, with good visibility into our capital business, we continue to anticipate a strong second half of the year in Medical Systems." Gallahue added, "During the quarter, we continued to make strategic progress, closing our Sendal acquisition in Spain as part of our strategy to globalize the company and ramping up our R&D investments in the Procedural Solutions segment as we prepare to launch several new products over the next 18 months." The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4933_CFN] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Financial Results, New Appointments, and Stock Price Movements - Research Report on Salix Pharmaceuticals, Cigna, St. Jude
Press spacebar to pause and continue. Press esc to stop.